The impurity is known as N-nitrosodiethylamine, classified as a probable human carcinogen.
The 22 batches were supplied to ScieGen Pharmaceuticals for manufacturing finished Irbesartan tablets in the U.S.
The affected lots, manufactured by ScieGen, have been labeled as Westminster Pharmaceuticals and Golden State Medical Supply. The 75-milligram, 150-milligram and 300-milligram tablets are part of the recall.
More articles on pharmacy:
Pfizer may sell its $2B women’s health unit
CVS pilots membership program to take on Amazon
Regional hospitals want in on lucrative drug trials
